HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
HemoGenyx Pharmaceuticals has announced the development of an enhanced bi-specific antibody, CDX, aimed at improving treatment for acute myeloid leukemia (AML) and certain types of acute lymphoblastic leukemia (ALL), as well as potential use in bone marrow transplant conditioning. This new version, developed using Lonza’s bYlok technology, has shown increased efficacy in preliminary tests, with further in vivo studies in progress. The breakthrough could lead to better patient outcomes and attract partnerships for accelerated development.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.
